RESUMEN
Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 (GRAVID). Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021. Results One hundred-fifty cases were registered. Median age was 68 years (range 695), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: FebruaryMay 2020, AugustNovember 2020, and December 2020April 2021. The first wave had the highest number of registered cases and COVID-19 mortality. Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection (AU)
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Infecciones por Coronavirus/mortalidad , Pandemias , Melanoma/mortalidad , Neoplasias Cutáneas/mortalidad , Índice de Severidad de la Enfermedad , España/epidemiologíaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Eritema/tratamiento farmacológico , Biopsia , Conjuntivitis/diagnóstico , Conjuntivitis/tratamiento farmacológico , Pronóstico , Astenia/diagnóstico , Astenia/etiología , Eritema/complicaciones , Leucocitosis/complicaciones , Leucocitosis/patologíaRESUMEN
La tiña del cuero cabelludo es una enfermedad muy rara en adultos. Presentamos una tinea capitis causada por Microsporum canis en una paciente sana postmenopáusica. Se discuten los factores predisponentes de la dermatofitosis en los pacientes adultos y se cuestiona el uso de terbinafina como tratamiento de primera elección en esta entidad, debido a la aparición de resistencias
Tinea capitis is very rare in adults. We report a new case of tinea capitis caused by Microsporum canis in a healthy postmenopausal woman. We argue the predisposing factors of the dermatophytoses in adult patients and discuss about the use of terbinafine like first line of treatment in this entity, because of the apparition of resistances